Qure.ai Gets Expanded FDA Clearance
The FDA has cleared six new indications for Qure.ai's qXR-Detect chest X-ray product. The expanded approval allows the AI tool to detect lung nodules, pleural effusion, and consolidation, among other findings. This significantly broadens the clinical use of the AI for triage, reporting, and decision support in radiology.
This latest clearance brings Qure.ai’s total to 26 FDA-cleared indications across nine of its products for X-ray and CT scans. The company’s qXR-Detect is also the only chest X-ray computer-assisted detection tool cleared by the FDA with a Predetermined Change Control Plan (PCCP), which will allow customers to get the most updated versions of the algorithm as it evolves. The approval comes as the entire U.S. imaging market is seeing a significant shift in volume from hospitals to outpatient centers, with outpatient imaging growth now outpacing the overall radiology market. This trend is driven by payors pushing for non-emergency imaging to be done in lower-cost settings and by patient demand for more convenient access. In response, many health systems are acquiring, developing, or forming joint ventures with freestanding imaging assets to recapture patient volume. This site-of-care shift creates a significant opening for mobile imaging providers who can offer services to diverse locations like nursing homes, assisted living facilities, and other residential settings. Mobile services reduce transportation complexities and costs for facilities, lessen anxiety for fragile patients, and can speed up diagnosis and treatment by bringing the imaging to the patient. Reimbursement for mobile services often includes separate payments for transportation and equipment setup, in addition to the radiological service itself. The demand for imaging is rising just as the healthcare industry faces a critical shortage of radiologists and technologists. Projections show that even with a 25.7% growth in the number of radiologists by 2055, it may not be enough to meet the anticipated 26.9% rise in imaging demand. The vacancy rate for CT technologists hit a high of 19.4% in 2025, and about 46% of radiologists report burnout, with attrition rates doubling from 2014 to 2022. AI tools like qXR-Detect are positioned to help imaging providers address these staffing challenges and operational pressures. By automating initial image analysis and prioritizing urgent cases, AI can optimize workflows, improve patient throughput, and reduce the administrative burden on stretched clinical teams. This allows radiologists and technologists to focus on more complex cases and patient-facing care. The American College of Radiology (ACR) is actively involved in guiding the implementation of AI in clinical practice. The ACR has launched programs like ARCH-AI to certify that practices have the necessary infrastructure for AI integration and Assess-AI, a national registry to monitor the real-world performance of AI algorithms. These initiatives aim to ensure that the adoption of AI is safe, effective, and responsible.
